Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.87
+0.91 (6.52%)
At close: Aug 10, 2026, 4:00 PM EDT
14.79
-0.08 (-0.54%)
Pre-market: Aug 11, 2026, 4:55 AM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.34. The average 1-year stock price forecast is 90.59% higher than the current stock price, while the lowest is $9.94 (-33.15%) and the highest is $41.44 (+178.68%).
Price Target: $28.34 (+90.59%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bernstein | Bernstein | Sell Reiterates $9.8 | Sell | Reiterates | $9.8 | -34.10% | Aug 11, 2026 |
| Barclays | Barclays | Hold Maintains $18 | Hold | Maintains | $18 | +21.05% | Aug 6, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 5, 2026 |
Unknown Analyst Clear Street No rating | Clear Street | Buy Maintains $31 | Buy | Maintains | $31 | +108.47% | Aug 3, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $41 | Buy | Maintains | $41 | +175.72% | Jul 29, 2026 |
Financial Forecast
Revenue This Year
4.09M
Revenue Next Year
59.71M
from 4.09M
Increased by 1,361.09%
EPS This Year
-1.16
from -1.44
EPS Next Year
-1.20
from -1.16
EPS and Forward PE are based on non-GAAP adjusted numbers.